Combined use of icariin and curcumin, and composition for cartilage repair
Through the combined use of icariin and curcumin, ROS-responsive cartilage-targeted hydrogel was prepared, combining carboxymethyl chitosan and polyvinyl alcohol, and the problem of poor cartilage injury repair in the prior art was solved. Cartilage repair and regeneration in an inflammatory environment has been achieved, which significantly improves the viability and proliferation of chondrocytes, and provides new treatment options for patients with knee osteoarthritis.
Patent Information
- Application Number
- CN202410989054.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-23
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art is difficult to effectively repair cartilage damage, especially in the environment of inflammatory and oxidative stress. Traditional therapies have little effect, and the hydrogels of a single material have insufficient mechanical properties and biocompatibility.
Using the combination of icariin and curcumin, ROS-responsive cartilage-targeted hydrogels are prepared, combining carboxymethyl chitosan and polyvinyl alcohol to form an injectable high-strength hydrogel for joint cavity Intravenous injection to promote cartilage repair and regeneration.
It has achieved the promotion of cartilage repair and regeneration in an inflammatory environment, improved the bioavailability of hydrophobic drugs, achieved sustained release effect, significantly improved the vitality and proliferation of chondrocytes, and provided a new combination of traditional Chinese medicine and tissue engineering. treatment options.
Smart Images

Figure CN118903172A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the combined use of icariin and curcumin, and a composition for cartilage repair. Background Technology
[0002] Cartilage, or cartilage tissue, is composed of chondrocytes and intercellular matrix. Cartilage damage is a significant cause of osteoarthritis. Treatment methods include medication, physical therapy, and lifestyle modifications. In terms of medication, glucosamine and chondroitin sulfate are commonly used drugs for repairing cartilage, promoting the synthesis of cartilage components and inhibiting their degradation. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as meloxicam and diclofenac sodium, have analgesic and anti-inflammatory effects and are commonly used to relieve pain in patellofemoral osteoarthritis of the knee.
[0003] According to a World Health Organization report, it is estimated that more than 350 million people worldwide will be disabled due to cartilage damage by 2030, placing a heavy burden on healthcare systems and patients. Articular cartilage defects are a common, non-self-healing clinical orthopedic condition, and traditional clinical treatments, including microfractures, cartilage allogeneic transplantation, joint replacement surgery, and bone marrow stem cell (MSC) injections, have yielded limited success. Controlled delivery and modulation techniques involving stem cells and chondrocytes have shown promise in cartilage regeneration. However, the pervasive inflammation and oxidative stress in the adverse cartilage injury microenvironment hinder cell survival and chondrogenic potential, leading to the formation of hypertrophic chondrocytes or replacement tissue. Therefore, reconstructing the physiological microenvironment is crucial for successful cartilage regeneration. In contrast, hydrogel-based tissue engineering is a promising strategy for promoting cartilage regeneration due to its simplicity and stable drug delivery capabilities. Chitosan, as a natural polymer with good biocompatibility and multiple functions, is also widely used in FDA-approved biomedical products.
[0004] Despite the numerous advantages of natural materials, the drawbacks of using a single material cannot be ignored. Adding polymers can improve their mechanical properties to some extent, enhancing their potential applications in tissue engineering. Polyvinyl alcohol (PVA) has become a popular material for tissue engineering repair due to its good biocompatibility, non-toxicity, and excellent mechanical properties. Previous studies have shown that the mechanical properties of PVA can be altered by adjusting its molecular weight, freeze-thaw cycles, and concentration. Furthermore, PVA can form hydrogels through physical cross-linking via freeze-thaw cycles, without the need for any chemical cross-linking agents. However, due to limitations in preparation conditions, injectable hydrogels often exhibit poor mechanical properties and are prone to swelling and degradation under physiological conditions, which can damage surrounding tissues and reduce their own mechanical strength. This significantly limits the practical application of hydrogels. A more robust and super-stretchable hydrogel, possessing a uniform and self-tunable network under stress, can be achieved through deformable and well-distributed nanoscale cross-linking, allowing for shape modification to disperse localized stress. The micelle crosslinking points can both inhibit the outward expansion of molecular chains under osmotic pressure and eliminate stress concentration through deformation when the gel is under stress, thus ensuring that the high crosslinking density network is not destroyed. The resulting injectable hydrogel possesses both non-swelling and high-strength properties, as well as good tissue adhesion, cell compatibility, and biodegradability. It also endows the gel with a slow and uniform degradation rate and can be used to encapsulate hydrophobic drugs.
[0005] Icariin is the main active ingredient extracted from the traditional Chinese medicine Epimedium, possessing various pharmacological effects, especially showing potential advantages in promoting the repair of articular cartilage damage (Liu Qi, et al., Research progress on the mechanism of action of icariin in promoting articular cartilage damage repair, Drug Evaluation Research, Vol. 47, No. 6, June 2024). Curcumin is a polyphenolic compound extracted from the ginger plant Curcuma longa, possessing various pharmacological effects, including antioxidant, anti-inflammatory, and anti-tumor effects. In recent years, the application of curcumin in cartilage repair and the treatment of osteoarthritis has attracted widespread attention. Curcumin has been shown to promote chondrocyte proliferation and chondrogenic differentiation, enhance chondrocyte viability and extracellular matrix formation (Biomaterials Advances (IF 5.5) Pub Date: 2017-02-16, DOI: 10.1016 / j.msec.2017.02.067). Curcumin also shows protective and repair effects on cartilage damage by inhibiting inflammatory responses and promoting chondrocyte proliferation and differentiation (Frontiers in Bioengineering and Biotechnology (IF 4.3) Pub Date: 2022-09-13, DOI: 10.3389 / fbioe.2022.994816).
[0006] CN202310857380.X, Invention Title: A Method for Preparing a Directed Osteocartilage Scaffold for In-situ Deposition of Drugs and Genes, discloses a method for preparing a directed cartilage scaffold for in-situ deposition of drugs and genes: A hydrogel precursor solution is poured into a mold to prepare a patterned hydrogel membrane including an upper groove and a lower groove; a suspension of nanoparticles containing cartilage repair and regeneration drugs and a polyphenol compound / buffer solution containing catechol are transferred to the upper groove, and cartilage repair drugs@catechol-containing polyphenol compound nanoparticles are synthesized in-situ on the hydrogel membrane; a solution containing bone regeneration gene drugs / CaCl2 and Na2HPO4 is transferred to the lower groove, and bone regeneration gene drugs@amorphous calcium phosphate nanoparticles are synthesized in-situ on the hydrogel membrane; based on the structure of Haversian tubules in natural bone units, the patterned hydrogel membrane is rolled into a cylindrical shape using a simple and efficient film-rolling method to form a directed cartilage scaffold.
[0007] There are currently no literature reports on the combined use of icariin and curcumin. Summary of the Invention
[0009] Based on current research, this invention explores the repair effect of carboxymethyl chitosan / polyvinyl alcohol (PVA) / 4-formylphenylboronic acid (PBA) hydrogel loaded with curcumin (CUR) and icariin (Ica) on cartilage defects in the knee joint of SD rats, providing a new approach for treating cartilage defects in patients with knee osteoarthritis by combining traditional Chinese medicine monomers with tissue engineering techniques. This invention also provides the use of icariin and curcumin in combination in the preparation of drugs for cartilage repair. Furthermore, this invention provides a composition for cartilage repair.
[0010] This invention provides the use of icariin and curcumin in combination in the preparation of a cartilage repair drug.
[0011] More preferably, the mass ratio of icariin to curcumin is 1:(1-4).
[0012] The mass ratio of icariin to curcumin is 1:3.
[0013] This invention provides a composition for cartilage repair, which is prepared from the following raw materials in the indicated weight ratios:
[0014] 1 part of icariin and 1-4 parts of curcumin.
[0015] More preferably, it is prepared from raw materials in the following weight ratio:
[0016] 1 part icariin and 3 parts curcumin.
[0017] The composition of this invention is prepared into a commonly used pharmaceutical formulation by adding pharmaceutically acceptable excipients or auxiliary ingredients, with icariin and curcumin as active ingredients.
[0018] The formulations mentioned are intra-articular injection solutions and ROS-responsive cartilage-targeting hydrogels.
[0019] The hydrogel is prepared by using icariin and curcumin as active ingredients, utilizing a nano micelle system made of mannose, polyethylene glycol and polycaprolactone, and then mixing it with carboxymethyl chitosan grafted with phenylboronic acid.
[0020] The present invention also provides the use of the described composition in the preparation of a medicament for intra-articular use in cartilage repair.
[0021] This invention combines icariin and curcumin for cartilage repair, exhibiting a synergistic effect. Icariin and curcumin are formulated into a ROS-responsive cartilage-targeting hydrogel, which is administered via intra-articular injection. This hydrogel mimics the mechanical properties of natural cartilage, promoting cartilage repair and regeneration while regulating inflammation. It targets joint macrophages, modulates the immune system, and improves the bioavailability of the hydrophobic drug, achieving a sustained-release effect. This combination of traditional Chinese medicine and cartilage tissue engineering provides a new clinical option. Attached Figure Description
[0022] Figure 1 Schematic diagram of the synthesis of targeted nanomicelles;
[0023] Figure 2 Schematic diagram of hydrogel synthesis;
[0024] Figure 3 Figure 1 shows the cartilage repair results of different base solution formulations of Ica and CUR. Detailed Implementation
[0025] Example 1: Preparation of the drug of the present invention
[0026] Weigh out 10 mg each of curcumin and icariin and dissolve them in 1 ml of dimethyl sulfoxide (DMSO) to obtain a concentration of 10 mg / ml. Then dilute the solution 1000 times to obtain a 10 μg / ml curcumin and icariin solution.
[0027] Example 2: Preparation of icariin and curcumin (PMPP / Ica@CUR) of the present invention
[0028] 1. Materials
[0029] Carboxymethyl chitosan (CMCS, Mn = 100,000–200,000, degree of deacetylation 90%, degree of carboxymethyl substitution 80%, the corresponding chitosan is extracted from the shells of shrimp and crab), polyvinyl alcohol (PVA), curcumin (CUR), 4-formylphenylboronic acid (PBA), sodium borohydride (NaBH4), ε-caprolactone, α,ω-dicarboxylated polyethylene glycol (COOH-PEG-COON), curcumin, icariin, D-mannosamine hydrochloride, N-tert-butoxycarbonyl-1,2-ethylenediamine, dicyclohexylcarbodiimide (DCC), N-hydroxythiosuccinimide (NHS).
[0030] 2. Synthesis of phenylboronic acid grafted carboxymethyl chitosan / polyvinyl alcohol (CMCS-PBA / PVA)
[0031] 2.1 Synthesis of phenylboronic acid grafted carboxymethyl chitosan (CMCS-PBA)
[0032] CMCS-PBA was synthesized via amidation. To synthesize CMCS-PBA, CMCS was dissolved in 90 mL of H₂O / DFM (3:2, v / v). 0.4 g of PBA, 0.46 g of EDC (1-ethyl-3-carbodiimide hydrochloride), and 0.33 g of NHS were dissolved in a 20 mL H₂O / DFM centrifuge tube. The mixture was reacted at room temperature for 30 minutes to activate the carboxyl groups, and then added to the CMCS solution. The solution pH was maintained in the range of 5–5.5 for 24 h. After the reaction was complete, the mixture was purified by dialyzing with 1% Na₂CO₃ solution for 2 days, followed by dialyzing with deionized water for 3 days, and then lyophilized. The final product was analyzed by proton nuclear magnetic resonance (NMR)... 1H NMR, 400MHz JEOL JNM-ECZ400S / L1) confirmed the successful grafting. (Reference: [1] Zhang D, Yu G, Long Z, et al. Controlable layer-by-layer assembly of PVA and phenylboronic acid-derivatized chitosan. Carbohydrate Polymers, 2016, 140 (228-232. [2] Guo Q, Yin T, Huang W, et al. Hybrid Hydrogels for Immunoregulation and Proangiogenesis through Mild Heat Stimulation toAccelerate Whole-Process Diabetic Wound Healing. Advanced HealthcareMaterials, 2024,13(18):2304536.)
[0033] 2.2 Preparation of drug-loaded nanomicelles, see the roadmap below. Figure 1 .
[0034] 2.2.1 Synthesis of monoprotected polycaprolactone (Boc-PCL)
[0035] Boc-PCL was synthesized by ring-opening polymerization of ε-caprolactone using Boc-NH-NH2 as a primer and SnCl2 as a catalyst. The procedure was as follows: Boc-NH-NH2 (0.12 g, 0.75 mmol), ε-caprolactone (3 g, 26 mmol), and SnCl2 (0.03 g) were added together to a 25 mL single-necked flask equipped with a vacuum stopcock. After vacuum drying at room temperature for 5 hours, ring-opening polymerization was carried out at 140 °C for 6 hours. Afterward, the mixture was cooled to room temperature, dissolved in 3 mL of dichloromethane, and then precipitated by adding excess ice-cold ethanol under vigorous stirring. The precipitated product was filtered and then vacuum dried for 24 hours to obtain the product Boc-NH-PCL.
[0036] 2.2.2 Synthesis of α,ω-dicarboxylated polyethylene glycol and polycaprolactone copolymer (PEG-PCL)
[0037] First, Boc-NH-PCL (1 g, 0.25 mmol) was dissolved in 10 mL of dichloromethane, followed by the addition of trifluoroacetic acid (150 μL) at room temperature. The reaction was carried out at room temperature under nitrogen protection until the reactants had completely reacted. Then, triethylamine (300 μL) was added to adjust the pH to weakly alkaline. The solvent was concentrated under reduced pressure, and excess triethylamine was removed. The solution was then redissolved in 30 mL of dichloromethane. Next, COOH-PEG-COOH (0.7 g, 0.35 mmol), DMAP (42 mg, 0.34 mmol), and DCC (71 mg, 0.34 mmol) were added. The mixture was stirred at room temperature under nitrogen protection for at least 48 hours, and TLC was used to monitor the reaction until the NH2-PCL reaction was complete. The reaction was then quenched with 1 mL of deionized water. Finally, the white solid (dicyclohexylurea) in the reaction system was filtered off, and the filtrate was concentrated under reduced pressure. The residue was redissolved in 10 mL of ethyl acetate, placed at 0 °C for 12 hours, the solid was filtered off, and the filtrate was concentrated to dryness again under reduced pressure. The residue was redissolved in 2 mL of dichloromethane, and a large amount of ethanol was added to precipitate it. The white solid that precipitated was filtered and vacuum dried for 24 hours to obtain the product COOH-PEG-PCL.
[0038] 2.2.3 Synthesis of Mannose-Modified PEG-PCL Polymer
[0039] D-Mannose-PEG-PCL (39 mg, 180 nmol) and triethylamine (22.5 mg, 222 nmol) were added together to 1 mL of DMF for desalting and dissolution to obtain a D-Mannose-PEG-PCL solution. COOH-PEG-PCL (1 g, 167 nmol) was dissolved in 10 mL of DMF, followed by the sequential addition of NHS (38.4 mg, 334 nmol) and EDC (51.8 mg, 334 nmol). After magnetic stirring at room temperature for 30 minutes, the above D-Mannose-PEG-PCL solution was added. The reaction was carried out at room temperature for more than 48 hours, followed by dialyzing with a dialysis bag (MWCO 3500) for 2 days, and then lyophilized to obtain the product Mannose-PEG-PCL.
[0040] 2.2.4 Preparation of nanomicelles
[0041] Micelles were prepared using a common solvent evaporation method. The specific procedure was as follows: 10 mg of Mannose-PEG-PCL polymer was dissolved in 10 mL of tetrahydrofuran. While magnetically stirring at 300 rpm, the polymer solution was added dropwise to 10 mL of ultrapure water. After the polymer solution was completely added, the stirring speed was reduced to 200 rpm, and stirring continued until the tetrahydrofuran was completely evaporated, yielding the Mannose-PEG-PCL micelle solution. The preparation method for drug-loaded micelles was the same: 1 mg of CUR and 10 mg of Mannose-PEG-PCL polymer were dissolved in 10 mL of tetrahydrofuran. This solution was then added dropwise to 10 mL of ultrapure water under uniform stirring. After the tetrahydrofuran evaporated, the micelle solution was placed in a dialysis bag (MWCO 3500) for dialysis to remove unloaded CUR, and then lyophilized to obtain CUR-loaded micelle lyophilized powder.
[0042] 3. Synthesis of hydrogel (PMPP / Ica@CUR)
[0043] CMCS-PBA was dissolved in 40 mg / mL deionized water, and then a 10% w / v PVA solution was dissolved in deionized water at 90℃. A certain amount of Ica was weighed and dissolved in ethanol solution, and then added to the PVA solution. The mixture was heated and stirred until the ethanol evaporated. The two solutions were then mixed thoroughly at 50℃ with a suitable concentration of Mannose-PEG-PCL@CUR solution in a 1:1 mass ratio. The mixture was sonicated for 3 min to remove air bubbles, resulting in a CMCS-PBA / PVA / Ica / Mannose-PEG-PCL@CUR hydrogel, denoted as PMPP / Ica@CUR (synthesis diagram shown in [reference needed]). Figure 2 ).
[0044] The following pharmacodynamic tests demonstrate the beneficial effects of this invention.
[0045] Experimental Example 1: Screening Test of the Combined Use Ratio of Icariin and Curcumin in this Invention
[0046] I. Experimental Procedure:
[0047] The chondrocyte suspension was prepared at 1.0*10 4 Cells were seeded at a density of 10 cells / ml into 96-well plates.
[0048] After culturing for 24 hours, chondrocytes were stimulated with 10 ng / ml lipopolysaccharide (LPS) for 8 hours to establish an inflammatory model. The inflammatory chondrocytes were then treated with a control group of the following mixtures: icariin and curcumin (1:1), icariin and curcumin (1:2), icariin and curcumin (1:3), icariin and curcumin (1:4), icariin and curcumin (1:5), icariin and curcumin (2:1), icariin and curcumin (3:1), icariin and curcumin (4:1), icariin and curcumin (5:1), icariin and curcumin (PMPP / Ica@CUR), icariin (10 μg / ml), curcumin (10 μg / ml), and chondrocyte culture medium. The drug concentration was 10 μg / ml. After 24 hours, the viability and proliferation of chondrocytes were detected using the CCK-8 assay. The specific steps were as follows: after 24 hours, culture medium was aspirated from 96-well plates, washed three times with PBS, and CCK-8 solution (culture medium: CCK-8 = 10:1) was added to each well. The cells were incubated at 37°C and then the OD value was measured using a microplate reader. The results are shown in Table 1 and [Table data missing]. Figure 1 As shown.
[0049] II. Statistical Analysis
[0050] All data were processed using GraphPad Prism 9 software (Table 1) and illustrated using mean SEM. Two-way ANOVA was used to analyze the MWM measurement-determined dataset, and one-way ANOVA was used to analyze the other data, followed by Tukey's post-hoc test. P < 0.05 was considered statistically significant.
[0051] III. Measurement Results
[0052] Table 1 shows the cartilage repair results of different base solutions containing icariin (Ica) and curcumin (CUR). It can be seen that the cartilage repair activity of icariin:curcumin = 1:3 (drug concentration 10 μg / ml) and hydrogel-loaded icariin and curcumin (PMPP / Ica@CUR) is superior to any combination of extracts. Cartilage proliferation results (n=5).
[0053] Table 1. Results of different base fluid formulations for ICA and CUR on cartilage repair.
[0054] Name and Scale OD value Dosage of icariin and curcumin Icariin and curcumin (1:1) 183.214±4.42 Icariin and curcumin (10μg:10μg) Icariin and curcumin (1:2) 188.776±5.065 Icariin and curcumin (7μg: 14μg) Icariin and curcumin (1:3) 198.422±4.885 Icariin and curcumin (5μg: 15μg) Icariin and curcumin (1:4) 157.246±2.395 Icariin and curcumin (4μg: 16μg) Icariin and curcumin (1:5) 70.906±7.18 Icariin and curcumin (3.5μg: 17.5μg) Icariin and curcumin (2:1) 119.560±7.46 Icariin and curcumin (14μg: 7μg) Icariin and curcumin (3:1) 80.004±2.76 Icariin and curcumin (15μg:15μg) Icariin and curcumin (4:1) 78.126±1.38 Icariin and curcumin (16μg: 4μg) Icariin and curcumin (5:1) 48.400±1.015 Icariin and curcumin (17.5 μg: 3.5 μg) Icariin and curcumin (PMPP / Ica@CUR) 226.852±14.94 Icariin and curcumin (10μg:10μg) Icariin (10 μg / ml) 131.335±3.5 Icariin and curcumin (10μg: 0μg) Curcumin (10μg / ml) 112.336±2.15 Icariin and curcumin (0μg: 10μg) 0 100±4.685 Icariin and curcumin (0μg: 0μg)
[0055] From Table 1, Figure 3The measured data show that Ica and CUR alone have significant therapeutic effects compared to the control group (group 0). At the same dosage, the efficacy of Ica and CUR in a 1:1 ratio is more obvious than that of the control group and the Ica and CUR alone group, with cartilage proliferation reaching 183.214±4.42. When Ica and CUR are in a 1:3 ratio, the therapeutic effect reaches the best effect, and its efficacy is nearly 2 times that of the control group.
[0056] The hydrogel-loaded group, namely the PMPP / Ica@CUR group, showed more than twice the increase compared to the control group. This demonstrates that the combined use of Ica and CUR effectively controls intra-articular inflammation, promoting cartilage repair and regeneration. Furthermore, the hydrogel enhances the therapeutic effect of the medication, allowing for on-demand release and long-term regulation.
Claims
1. Use of icariin in combination with curcumin in the preparation of drugs for cartilage repair.
2. The use according to claim 1, characterized in that: The mass ratio of icariin to curcumin is 1:(1-4).
3. The use according to claim 2, characterized in that: The mass ratio of icariin to curcumin is 1:
3.
4. A composition for cartilage repair, characterized in that: It is prepared from the following raw materials in weight ratio: 1 part of icariin and 1-4 parts of curcumin.
5. The composition for cartilage repair according to claim 4, characterized in that: It is prepared from the following raw materials in weight ratio: 1 part of icariin and 3 parts of curcumin.
6. The composition for cartilage repair according to claim 4 or 5, characterized in that: The invention is prepared from icariin and curcumin as active ingredients, and pharmaceutically acceptable auxiliary materials or auxiliary ingredients are added to form a commonly used pharmaceutical preparation.
7. The composition for cartilage repair according to claim 6, characterized in that: The preparation is an intra-articular injection solution and a ROS-responsive cartilage-targeted hydrogel.
8. The composition for cartilage repair according to claim 7, characterized in that: The hydrogel is prepared by mixing icariin and curcumin as active ingredients, a nano-micelle system made of mannose, polyethylene glycol and polycaprolactone with phenylboronic acid grafted carboxymethyl chitosan.
9. Use of the composition according to any one of claims 4 to 8 in the preparation of a medicament for intra-articular administration for cartilage repair.
